Breast MRI for Neaodjuvant Chemotherapy Response Prediction and Evaluation in Breast Cancer

Breast Cancer Clinical Trial

Official title:

Breast MRI for Neaodjuvant Chemotherapy Response Prediction and Evaluation in Breast Cancer, With Focus on Background Parenchymal Enhancement

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03580837
• Other study ID #: 6788
• Status: Recruiting
• Start date: January 1, 2018
• Est. completion date: January 2019

Study information

• Verified date: January 2018
• Source: University Hospital, Strasbourg, France
• Contact: Sébastien MOLIERE, MD
• Phone: 33 3 88 12 78 65
• Email: sebastien.moliere[@]chru-strasbourg.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this retrospective study is to evaluate the value of pre-treatment and post-treatment multimodality MRI study, including quantitative evaluation of background parenchymal enhancement, for response prediction and evaluation. This study will include 100 patients treated in a single institution between 2011 and 2016

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: January 2019
• Est. primary completion date: January 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients

• Patients with breast cancer treated with neoadjuvant chemotherapy

• Patients with pre- and post-chemotherapy MRI

• Patients who have given their agreement to use their data for research purposes.

Exclusion Criteria:

• Refusal to participate in the study

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Locations

Country	Name	City	State
France	Service Imagerie 1	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Presence or absence of of pathologic enhancement of breast by MRI	This work concerns 110 patients treated with neoadjuvant chemotherapy for breast cancer and having received a breast MRI in pre and post-chemiotherapy at the Hautepierre Hospital.	1 hour after the realization of the MRI